Too bad he is not spending the time updating current shareholders on the status of this company's financials, debt level, share structure, patents, legal proceedings, and a host of other issues. I fully expect this interview to be nothing more than the other interviews he has done in the past. It is time for details regarding the business not another overview of autologous stromal vascular fraction cell therapy.
News 
Market Data 
Discover 
